» Articles » PMID: 28698338

Optimal Cut Points of Plasma and Urine Neutrophil Gelatinase-associated Lipocalin for the Prediction of Acute Kidney Injury Among Critically Ill Adults: Retrospective Determination and Clinical Validation of a Prospective Multicentre Study

Overview
Journal BMJ Open
Specialty General Medicine
Date 2017 Jul 13
PMID 28698338
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To determine the optimal threshold of blood and urine neutrophil gelatinase-associated lipocalin (NGAL) to predict moderate to severe acute kidney injury (AKI) and persistent moderate to severe AKI lasting at least 48 consecutive hours, as defined by an adjudication panel.

Methods: A multicentre prospective observational study enrolled intensive care unit (ICU) patients and recorded daily ethylenediaminetetraacetic acid (EDTA) plasma, heparin plasma and urine NGAL. We used natural log-transformed NGAL in a logistic regression model to predict stage 2/3 AKI (defined by Kidney Disease International Global Organization). We performed the same analysis using the NGAL value at the start of persistent stage 2/3 AKI.

Results: Of 245 subjects, 33 (13.5%) developed stage 2/3 AKI and 25 (10.2%) developed persistent stage 2/3 AKI. Predicting stage 2/3 AKI revealed the optimal NGAL cutoffs in EDTA plasma (142.0 ng/mL), heparin plasma (148.3 ng/mL) and urine (78.0 ng/mL) and yielded the following decision statistics: sensitivity (SN)=78.8%, specificity (SP)=73.0%, positive predictive value (PPV)=31.3%, negative predictive value (NPV)=95.7%, diagnostic accuracy (DA)=73.8% (EDTA plasma); SN=72.7%, SP=73.8%, PPV=30.4%, NPV=94.5%, DA=73.7% (heparin plasma); SN=69.7%, SP=76.8%, PPV=32.9%, NPV=94%, DA=75.8% (urine). The optimal NGAL cutoffs to predict persistent stage 2/3 AKI were similar: 148.3 ng/mL (EDTA plasma), 169.6 ng/mL (heparin plasma) and 79.0 ng/mL (urine) yielding: SN=84.0%, SP=73.5%, PPV=26.6%, NPV=97.6, DA=74.6% (EDTA plasma), SN=84%, SP=76.1%, PPV=26.8%, NPV=96.5%, DA=76.1% (heparin plasma) and SN=75%, SP=75.8%, PPV=26.1, NPV=96.4%, DA=75.7% (urine).

Conclusion: Blood and urine NGAL predicted stage 2/3 AKI, as well as persistent 2/3 AKI in the ICU with acceptable decision statistics using a single cut point in each type of specimen.

Citing Articles

Advances in kidney disease: pathogenesis and therapeutic targets.

Boima V, Agyekum A, Ganatra K, Agyekum F, Kwakyi E, Inusah J Front Med (Lausanne). 2025; 12:1526090.

PMID: 40027896 PMC: 11868101. DOI: 10.3389/fmed.2025.1526090.


10 tips on how to use dynamic risk assessment and alerts for AKI.

Quickfall D, La A, Koyner J Clin Kidney J. 2024; 17(11):sfae325.

PMID: 39588357 PMC: 11586629. DOI: 10.1093/ckj/sfae325.


The role of biomarkers in early identification of acute kidney injury among non-critically ill patients.

Safadi S, Hommos M, Thongprayoon C, Giesen C, Bernaba M, Kashani K J Nephrol. 2024; 37(5):1327-1338.

PMID: 38837000 DOI: 10.1007/s40620-024-01950-7.


Impact of low pneumoperitoneum on renal function and acute kidney injury biomarkers during robot-assisted radical prostatectomy (RARP): a randomised clinical trial.

Alhusseinawi H, Sander L, Handberg A, Rasmussen R, Kingo P, Jensen J J Robot Surg. 2024; 18(1):31.

PMID: 38231282 PMC: 10794424. DOI: 10.1007/s11701-023-01744-2.


Evaluation of plasma and urine neutrophil gelatinase-associated lipocalin (NGAL) as an early diagnostic marker of acute kidney injury (AKI) in critically ill trauma patients.

Gupta B, Tiwari P, Subramanian A, Mahajan S, Kalaivani M, Bindra A J Anaesthesiol Clin Pharmacol. 2023; 39(2):292-301.

PMID: 37564858 PMC: 10410041. DOI: 10.4103/joacp.joacp_284_21.


References
1.
Kashani K, Al-Khafaji A, Ardiles T, Artigas A, Bagshaw S, Bell M . Discovery and validation of cell cycle arrest biomarkers in human acute kidney injury. Crit Care. 2013; 17(1):R25. PMC: 4057242. DOI: 10.1186/cc12503. View

2.
McCullough P, Shaw A, Haase M, Bouchard J, Waikar S, Siew E . Diagnosis of acute kidney injury using functional and injury biomarkers: workgroup statements from the tenth Acute Dialysis Quality Initiative Consensus Conference. Contrib Nephrol. 2013; 182:13-29. DOI: 10.1159/000349963. View

3.
McCullough P, Bouchard J, Waikar S, Siew E, Endre Z, Goldstein S . Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contrib Nephrol. 2013; 182:5-12. PMC: 3856225. DOI: 10.1159/000349962. View

4.
Zhang A, Cai Y, Wang P, Qu J, Luo Z, Chen X . Diagnosis and prognosis of neutrophil gelatinase-associated lipocalin for acute kidney injury with sepsis: a systematic review and meta-analysis. Crit Care. 2016; 20:41. PMC: 4754917. DOI: 10.1186/s13054-016-1212-x. View

5.
Clerico A, Galli C, Fortunato A, Ronco C . Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences. Clin Chem Lab Med. 2012; 50(9):1505-17. DOI: 10.1515/cclm-2011-0814. View